Evidence map›Paper›PMID 27471715›Full record

ReviewImmunoTargets and therapy2015

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.

Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Xing Zhao, Holbrook E Kohrt

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ImmunoTargets and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.Medical oncology (Northwood, London, England) · 2022
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 3 countries.

Narendiran RajasekaranDivision of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA; Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
Cariad ChesterDivision of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA; Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
Atsushi YonezawaDivision of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA; Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
Xing ZhaoDivision of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA; Tissue Engineering and Stem Cells Research Center, Department of Immunology, Guiyang Medical University, Guiyang, Guizhou Province, People's Republic of China.
Holbrook E KohrtDivision of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA.
Stanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic efficacy of some anti-tumor monoclonal antibodies (mAbs) depends on the capacity of the mAb to recognize the tumor-associated antigen and induce cytotoxicity via a network of immune effector cells. This process of antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells is triggered by the interaction of the fragment crystallizable (Fc) portion of the mAb with the Fc receptors on effector cells like natural killer cells, macrophages, γδ T cells, and dendritic cells. By augmenting ADCC, the antitumor activity of mAbs can be significantly increased. Currently, identifying and developing therapeutic agents that enhance ADCC is a growing area of research. Combining existing tumor-targeting mAbs and ADCC-promoting agents that stimulate effector cells will translate to greater clinical responses. In this review, we discuss strategies for enhancing ADCC and emphasize the potential of combination treatments that include US Food and Drug Administration-approved mAbs and immunostimulatory therapeutics.

Indexed as

ADCCCD137NK cellreovirusTLR

Identifiers

PMID27471715
PMCPMC4918249
OpenAlexW1621402431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.